Wednesday, November 13, 2024

Immunotherapy drug pembrolizumab improves outcomes for patients with soft tissue sarcoma

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results of the SU2C-SARC032 clinical trial.

from Top Health News -- ScienceDaily https://ift.tt/1yPLs2U
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Study finds untreated sleep apnea doubles Parkinson’s risk

A massive veteran study found a strong connection between untreated sleep apnea and a higher chance of Parkinson’s. CPAP users had much lowe...